Skip to content
BHP

Survodutide safety profile & UK regulatory status

Research reference

Reviewed by the BestHealingPeptides Editorial Team ·

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Survodutide as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Survodutide is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

In the published trials the most common adverse events were gastrointestinal. In SYNCHRONIZE-1 (NEJM 2026) gastrointestinal adverse events occurred in 80.9% (3.6 mg) and 89.7% (6.0 mg) of participants versus 47.9% with placebo, and in SYNCHRONIZE-2 (NEJM 2026) in 72.8% and 77.7% versus 38.6%; the abstracts describe them as typically mild to moderate. In the Phase II MASH trial, nausea (66% vs 23%), diarrhoea (49% vs 23%) and vomiting (41% vs 4%) were more frequent with survodutide than with placebo, and serious adverse events occurred in 8% with survodutide and 7% with placebo (Sanyal et al., NEJM 2024). In the Phase II obesity trial adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, primarily gastrointestinal (le Roux et al., 2024).

Survodutide is not approved, so there is no UK Summary of Product Characteristics and no licensed contraindication or warning list. Other GLP-1 receptor agonist medicines carry labelled warnings, but this reference does not extend those to survodutide. Cardiovascular safety is the subject of a dedicated trial (SYNCHRONIZE-CVOT, NCT06077864), which ClinicalTrials.gov lists as completed; Boehringer Ingelheim had said it expected to present the results later in 2026 (Zealand Pharma announcement, 1 October 2026), and this reference has not found them.

Reported contraindications & cautions

  • Not a licensed medicine — there is no UK Summary of Product Characteristics and no formal contraindication list
  • Trial eligibility criteria are set by each trial protocol and are not a statement of medical contraindications

Known formulation interactions

  • No approved product information exists, so no interaction list can be cited. Anyone taking survodutide in a clinical trial should follow the trial team's advice on other medicines.

UK regulatory status

Survodutide is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of 29 October 2026; Zealand Pharma (1 October 2026) describes it as an investigational agent that has not been approved for use. Boehringer Ingelheim's Phase III SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD trials have been published; SYNCHRONIZE-CVOT results have not, and the LIVERAGE trials are ongoing. This reference did not find an announced regulatory submission to the MHRA, EMA or US FDA, and makes no claim about when one might be made.

Without a marketing authorisation, survodutide is not available as a medicine in the UK. Supply or administration to people outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012. Unregulated supply of clinical-development peptides carries substantial safety and regulatory risk.

Survodutide is not named on the WADA Prohibited List; WADA's S0 category covers pharmacological substances not addressed elsewhere on the List that have no current government approval for human therapeutic use, so athletes should check its status with their anti-doping organisation. Not a controlled drug under the Misuse of Drugs Act 1971. For animal research under ASPA, survodutide work in vertebrates requires standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Survodutide is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Survodutide research context including mechanism, study citations, and references, see the main Survodutide research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.